Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901 - Wikidata - wikimedia - TriplyDB

Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901

Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901

http://www.wikidata.org/entity/Q35100217

about

Hematopoietic cell transplantation for B-cell lymphoma: an update Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes.Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.Allogeneic hematopoietic cell transplantation in mantle cell lymphoma.Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma.Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells Hematopoietic cell transplantation for lymphomas.Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia.Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?Successful allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for B-cell prolymphocytic leukemia in partial remission.

P2860

Q27026617-DF2AA440-FAA3-459C-BFAE-E080100CC634 Q28066710-B16724E8-27AD-4CAB-BF22-716B6731B626 Q30248407-A2AA13B3-8054-4163-8074-5EA9A4F96CEA Q33419003-1EAC5E4A-8C94-4CA8-859F-D0ED7EE7C623 Q33958019-990F2C75-578A-43FD-92C5-7BBB73D14A5B Q35043077-48A62445-05D9-4D02-9453-D482CF5297B1 Q35166811-05AB114D-A3E7-4EB4-85CB-61F165D1C94B Q36028751-0F223DB5-06F7-4109-989D-76C98325274C Q36117647-851C3C33-2DF9-4587-95A3-4888452912FF Q36264884-31FCD9C1-464E-4A74-8EE6-F6C83B803DC9 Q36303065-2C6C654F-D27C-4921-BA47-4CB43123A370 Q36336614-7794F57D-66A9-41AF-BC5B-AC4215D1ADD8 Q36837761-76D83E8F-6253-4FDE-9461-9FC4F1FC44F5 Q36837797-FAA7CD60-4DAF-4993-A739-B2385DFC8F2C Q37123927-F1D4F91A-AE71-4F15-987D-EF454E411847 Q37942817-0E636530-79BF-4039-B167-B54012ABBFB7 Q38098957-E60A75C6-9F22-4BFB-88E2-3CD41729FD07 Q38488058-725DAA41-F447-4436-B900-10B3D77FCA9B Q38889962-DC1CE06B-2D6E-456A-8EFA-B7AD2D1520C0 Q40015002-C9DF3D36-64D2-4BFE-94F7-93CF29FD0BBF Q40744550-05A76DBA-3ECE-4404-BCB1-833CBC4FF55B Q40817438-B8A3C090-288C-4399-B5BC-53D502860320 Q44065098-AFFC80D4-F58B-4A22-B088-FD3BD40BE96B Q47174138-9268DE07-F560-4A6D-9E2B-625BEA65FC83 Q51756245-EC53C7CD-7C3E-42A2-9502-87216BAEBF2F

P2860

Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901

http://www.wikidata.org/entity/Q35100217

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Reduced-intensity allogeneic t ...... ell malignancies: CALGB 109901

@ast

Reduced-intensity allogeneic t ...... ell malignancies: CALGB 109901

@en

type

label

Reduced-intensity allogeneic t ...... ell malignancies: CALGB 109901

@ast

Reduced-intensity allogeneic t ...... ell malignancies: CALGB 109901

@en

prefLabel

Reduced-intensity allogeneic t ...... ell malignancies: CALGB 109901

@ast

Reduced-intensity allogeneic t ...... ell malignancies: CALGB 109901

@en

P1433

Q35100217-6BD4E145-3C0C-4E79-9048-2798C98F6638

P1476

Q35100217-FA0D6EFA-08D5-4579-B8F1-0E4884455D91

P2093

Q35100217-03F0D961-5618-416A-8482-3074FC388965

Q35100217-24B06CC8-0FD9-4194-AC68-3754104A20DB

Q35100217-27FD1548-87CA-4FD3-9DC3-4998F2A71F46

Q35100217-28486E30-B888-4E1B-AB58-AB533E870157

Q35100217-2EC39F9A-0136-4C25-AF19-4BB516C9F6C9

Q35100217-30DB6B53-E0CE-404B-8301-32462600AB59

Q35100217-611D6D53-8EB0-4E20-B98B-1C2B5C40BD1D

Q35100217-65A334DD-21BD-41E7-BAEF-D1329A260E9E

Q35100217-B844707A-614B-4C8C-884D-A64C44B1355C

Q35100217-C41DA102-3584-4837-B170-BF9F653BFDC5

P2860

Q35100217-0EA6D986-6275-4DCC-A6ED-EDD77D4538B0

Q35100217-0FA490EC-701D-4569-9911-4AD8595E7CAE

Q35100217-13C244E2-D14B-4D08-AB5D-D569E8E03D45

Q35100217-1A0E7464-D449-449E-917E-E457857C6D1C

Q35100217-2772D8CB-9D82-48D5-B407-3702B0C8AD2B

Q35100217-2C443C0E-BA6E-4499-A1A8-CDECE4A57B8A

Q35100217-310575F3-D349-4BD0-BC67-7E4ECE3D7638

Q35100217-3E612AD5-3870-4FDC-8BE5-D5B2267A79B5

Q35100217-49ABC604-2000-46A6-94C4-6DD302029105

Q35100217-4C593611-5D2F-4E40-87A4-22A02D23DC2E

P304

Q35100217-537E24BF-D547-4894-A97C-16E8940A26B0

P31

Q35100217-55B3DECE-FD44-4C18-9C20-B3C0194366BA

P356

Q35100217-786500AE-526B-4EC6-8D78-77E316CC6644

P433

Q35100217-3CC22C5A-9C4B-4B89-A851-ACB8C0F1C679

P478

Q35100217-881655EF-A342-4FC3-81F9-FB35575150B8

P50

Q35100217-0599DD76-F555-4750-BDCF-B338FEDF3D68

P577

Q35100217-8A581962-671E-4AC2-85CE-D9B3FB73FE2B

P5875

Q35100217-2FCF97D4-4B50-4821-A2BF-70EE7FF01B30

P698

Q35100217-A971A8A6-F81E-4205-96EC-A7B0E023F178

P921

Q35100217-EABF8620-6CCD-4403-A2E6-250668A264CF

P932

Q35100217-894F58DA-1B10-4539-8137-6AE8C88EFB26

P356

J.BBMT.2011.01.016

P1433

Biology of Blood and Marrow Transplantation

P1476

Reduced-intensity allogeneic t ...... ell malignancies: CALGB 109901

@en

P2093

Asad Bashey

http://www.w3.org/2001/XMLSchema#string

Charles Linker

http://www.w3.org/2001/XMLSchema#string

Jeffrey Johnson

http://www.w3.org/2001/XMLSchema#string

John McCarty

http://www.w3.org/2001/XMLSchema#string

Kouros Owzar

http://www.w3.org/2001/XMLSchema#string

Lee-Anne Baxter-Lowe

http://www.w3.org/2001/XMLSchema#string

Luis Isola

http://www.w3.org/2001/XMLSchema#string

Michael Kelly

http://www.w3.org/2001/XMLSchema#string

Peter Westervelt

http://www.w3.org/2001/XMLSchema#string

Sherif Farag

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

New treatment options have changed the survival of patients with follicular lymphoma.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.

Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.

Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study.

Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

P304

1395-1403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2011.01.016

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Cancer and Leukemia Group B

P577

2011-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49812995

http://www.w3.org/2001/XMLSchema#string

P698

21296675

http://www.w3.org/2001/XMLSchema#string

P921

fludarabine phosphate

P932

3134602

http://www.w3.org/2001/XMLSchema#string